Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
21 May 2018
Change (% chg)

$-0.03 (-2.22%)
Prev Close
$1.35
Open
$1.33
Day's High
$1.34
Day's Low
$1.31
Volume
11,522
Avg. Vol
60,702
52-wk High
$5.99
52-wk Low
$1.24

Chart for

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $38.41
Shares Outstanding(Mil.): 28.04
Dividend: --
Yield (%): --

Financials

  CYTR.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.12 -- --
ROI: -104.74 -8.07 12.63
ROE: -156.02 -10.87 14.50

BRIEF-CytRx Announces Closing Of $7.0 Mln Registered Direct Offering

* CYTRX ANNOUNCES CLOSING OF $7.0 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Cytrx Announces $7.0 Million Registered Direct Offering

* CYTRX - ENTERED PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO SELL IN REGISTERED DIRECT OFFERING 5.6 MILLION SHARES AT PRICE OF $1.25/SHARE Source text for Eikon: Further company coverage:

May 11 2018

BRIEF-Cytrx Reports First Quarter Loss Of $0.15 Per Share

* CASH AND CASH EQUIVALENTS OF $35.1 MILLION AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 08 2018

BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug Candidates

* CYTRX PRESENTS STATISTICALLY SIGNIFICANT BREAKTHROUGH DATA FOR ITS ALBUMIN BINDING ULTRA HIGH POTENCY LADR DRUG CANDIDATES

Apr 18 2018

BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

* CYTRX SELECTS FOUR NEW LADR™ ULTRA HIGH POTENCY DRUG CANDIDATES FOR ADVANCEMENT TOWARD CLINICAL TRIALS

Mar 15 2018

BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners

* CYTRX CORP - ANNOUNCED ITS ENTRY INTO A DEFINITIVE AGREEMENT WITH DESTUM PARTNERS

Feb 28 2018

Earnings vs. Estimates